HomeComparePOLBF vs EPRT

POLBF vs EPRT: Dividend Comparison 2026

POLBF yields 3344.48% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 POLBF wins by $1284463355857.04M in total portfolio value
10 years
POLBF
POLBF
● Live price
3344.48%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1284463355857.10M
Annual income
$1,213,110,815,498,324,000.00
Full POLBF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — POLBF vs EPRT

📍 POLBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPOLBFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, POLBF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
POLBF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

POLBF
Annual income on $10K today (after 15% tax)
$284,280.94/yr
After 10yr DRIP, annual income (after tax)
$1,031,144,193,173,575,300.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, POLBF beats the other by $1,031,144,193,173,564,400.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of POLBF + EPRT for your $10,000?

POLBF: 50%EPRT: 50%
100% EPRT50/50100% POLBF
Portfolio after 10yr
$642231677928.58M
Annual income
$606,555,407,749,168,400.00/yr
Blended yield
94.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

POLBF
No analyst data
Altman Z
39.8
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

POLBF buys
0
EPRT buys
0
No recent congressional trades found for POLBF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPOLBFEPRT
Forward yield3344.48%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$1284463355857.10M$63.4K
Annual income after 10y$1,213,110,815,498,324,000.00$12,840.73
Total dividends collected$1279557275592.29M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: POLBF vs EPRT ($10,000, DRIP)

YearPOLBF PortfolioPOLBF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$345,148$334,448.16$11,205$505.18+$333.9KPOLBF
2$11,157,548$10,788,239.94$12,672$682.46+$11.14MPOLBF
3$337,872,856$325,934,279.31$14,490$930.48+$337.86MPOLBF
4$9,585,767,941$9,224,243,985.35$16,786$1,282.69+$9585.75MPOLBF
5$254,836,586,625$244,579,814,927.95$19,753$1,791.56+$254836.57MPOLBF
6$6,349,429,806,239$6,076,754,658,549.98$23,677$2,541.64+$6349429.78MPOLBF
7$148,295,333,941,378$141,501,444,048,701.88$29,008$3,672.99+$148295333.91MPOLBF
8$3,247,334,232,557,481$3,088,658,225,240,206.50$36,463$5,425.08+$3247334232.52MPOLBF
9$66,684,617,157,738,690$63,209,969,528,902,180.00$47,238$8,221.57+$66684617157.69MPOLBF
10$1,284,463,355,857,104,100$1,213,110,815,498,324,000.00$63,385$12,840.73+$1284463355857.04MPOLBF

POLBF vs EPRT: Complete Analysis 2026

POLBFStock

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class intranasally administered RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Full POLBF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this POLBF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

POLBF vs SCHDPOLBF vs JEPIPOLBF vs OPOLBF vs KOPOLBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.